Equities analysts expect Wave Life Sciences Ltd (NASDAQ:WVE) to post earnings of ($1.25) per share for the current fiscal quarter, Zacks Investment Research reports. Five analysts have provided estimates for Wave Life Sciences’ earnings, with the highest EPS estimate coming in at ($1.05) and the lowest estimate coming in at ($1.34). Wave Life Sciences posted earnings per share of ($0.94) in the same quarter last year, which would indicate a negative year over year growth rate of 33%. The firm is scheduled to announce its next quarterly earnings report on Thursday, November 8th.

On average, analysts expect that Wave Life Sciences will report full-year earnings of ($4.99) per share for the current financial year, with EPS estimates ranging from ($5.21) to ($4.66). For the next fiscal year, analysts anticipate that the firm will post earnings of ($2.88) per share, with EPS estimates ranging from ($5.03) to ($1.13). Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that follow Wave Life Sciences.

Wave Life Sciences (NASDAQ:WVE) last posted its quarterly earnings data on Thursday, August 9th. The company reported ($1.23) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.35) by ($0.88). Wave Life Sciences had a negative return on equity of 91.88% and a negative net margin of 1,473.26%. The firm had revenue of $4.88 million during the quarter, compared to the consensus estimate of $7.38 million.

Several research analysts recently commented on WVE shares. ValuEngine raised shares of Wave Life Sciences from a “hold” rating to a “buy” rating in a report on Saturday, June 2nd. TheStreet downgraded shares of Wave Life Sciences from a “c-” rating to a “d+” rating in a report on Thursday, May 31st. BidaskClub raised shares of Wave Life Sciences from a “buy” rating to a “strong-buy” rating in a report on Thursday, June 7th. Stifel Nicolaus started coverage on shares of Wave Life Sciences in a report on Monday, August 6th. They issued a “buy” rating and a $56.00 price objective for the company. Finally, Mizuho set a $65.00 price objective on shares of Wave Life Sciences and gave the stock a “buy” rating in a report on Thursday, August 9th. One analyst has rated the stock with a sell rating, five have issued a buy rating and two have given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $58.40.

Shares of WVE stock traded down $0.35 during trading hours on Tuesday, hitting $54.85. 6,952 shares of the company were exchanged, compared to its average volume of 105,634. The company has a quick ratio of 6.11, a current ratio of 6.11 and a debt-to-equity ratio of 0.05. Wave Life Sciences has a 52-week low of $21.00 and a 52-week high of $56.00. The firm has a market cap of $1.53 billion, a P/E ratio of -14.25 and a beta of 0.93.

In other news, insider Chris Francis sold 24,496 shares of the firm’s stock in a transaction on Monday, July 9th. The shares were sold at an average price of $37.27, for a total transaction of $912,965.92. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 44.20% of the company’s stock.

Several institutional investors have recently bought and sold shares of WVE. Spark Investment Management LLC raised its position in Wave Life Sciences by 38.1% in the 2nd quarter. Spark Investment Management LLC now owns 155,600 shares of the company’s stock worth $5,951,000 after purchasing an additional 42,900 shares during the period. UBS Group AG raised its position in Wave Life Sciences by 26.0% in the 1st quarter. UBS Group AG now owns 8,356 shares of the company’s stock worth $335,000 after purchasing an additional 1,723 shares during the period. BB Biotech AG raised its position in Wave Life Sciences by 27.0% in the 2nd quarter. BB Biotech AG now owns 1,137,885 shares of the company’s stock worth $43,524,000 after purchasing an additional 241,789 shares during the period. DAFNA Capital Management LLC raised its position in Wave Life Sciences by 7.9% in the 2nd quarter. DAFNA Capital Management LLC now owns 47,900 shares of the company’s stock worth $1,832,000 after purchasing an additional 3,500 shares during the period. Finally, Point72 Asset Management L.P. raised its position in Wave Life Sciences by 727.4% in the 2nd quarter. Point72 Asset Management L.P. now owns 350,000 shares of the company’s stock worth $13,388,000 after purchasing an additional 307,700 shares during the period. Hedge funds and other institutional investors own 83.42% of the company’s stock.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a biotechnology company, designs, develops, and commercializes nucleic acid therapeutic candidates for genetically defined diseases by utilizing proprietary synthetic chemistry drug development platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

See Also: What is a stock split?

Get a free copy of the Zacks research report on Wave Life Sciences (WVE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Wave Life Sciences (NASDAQ:WVE)

Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.